BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 17545791)

  • 1. Granulocyte colony-stimulating factors: finding the right indication.
    Lyman GH; Shayne M
    Curr Opin Oncol; 2007 Jul; 19(4):299-307. PubMed ID: 17545791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.
    Lyman GH; Kleiner JM
    Cancer Treat Res; 2011; 157():145-65. PubMed ID: 21052955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
    Bhana N
    Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy.
    Daniel DB; Crawford J;
    Curr Hematol Rep; 2005 Nov; 4(6):441-5. PubMed ID: 16232380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC).
    Grossi F; Tiseo M
    Crit Rev Oncol Hematol; 2006 Jun; 58(3):221-30. PubMed ID: 16697211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors.
    Timmer-Bonte JN; Tjan-Heijnen VC
    Anticancer Drugs; 2006 Sep; 17(8):881-9. PubMed ID: 16940798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutropenia management with granulocyte colony-stimulating factors: from guidelines to nursing practice protocols.
    Dolan S; Crombez P; Munoz M
    Eur J Oncol Nurs; 2005; 9 Suppl 1():S14-23. PubMed ID: 16207534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic factors for febrile neutropenia].
    Ray-Coquard I; Borg C; Bachelot T; Fayette J; Zufferey L; Guastalla JP; Ghesquière H; Blay JY; Sebban C; Marec-Bérard P; Biron P
    Bull Cancer; 2006 May; 93(5):501-6. PubMed ID: 16777629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nurses' guide to understanding and implementing the National Comprehensive Cancer Network guidelines for myeloid growth factors.
    Wilson BJ; Gardner AE
    Oncol Nurs Forum; 2007 Mar; 34(2):347-53. PubMed ID: 17573299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: Implications for oncology nurses.
    Kearney N; Friese C
    Eur J Oncol Nurs; 2008 Feb; 12(1):14-25. PubMed ID: 18291720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?
    Klastersky J; Awada A; Aoun M; Paesmans M
    Curr Opin Oncol; 2009 Jul; 21(4):297-302. PubMed ID: 19509500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia.
    Lyman GH
    Curr Opin Hematol; 2011 Jan; 18(1):1-10. PubMed ID: 21042215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.
    Heuser M; Ganser A; Bokemeyer C; ; ;
    Semin Hematol; 2007 Jul; 44(3):148-56. PubMed ID: 17631179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocytic growth factors and cancer-related neutropenia: limited effects.
    Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of hematopoietic growth factors in oncology].
    Delmer A; Zittoun R
    Bull Cancer; 1991; 78(2):115-31. PubMed ID: 2036483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of myeloid growth factors in cancer chemotherapy.
    Lyman GH; Kuderer NM
    Curr Hematol Rep; 2003 Nov; 2(6):471-9. PubMed ID: 14561391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients.
    Zielinski CC; Awada A; Cameron DA; Cufer T; Martin M; Aapro M
    Eur J Cancer; 2008 Feb; 44(3):353-65. PubMed ID: 18191396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal use of granulocyte-colony-stimulating factor in patients with cancer who are at risk for chemotherapy-induced neutropenia.
    Cappozzo C
    Oncol Nurs Forum; 2004 May; 31(3):569-76. PubMed ID: 15146222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia.
    Lyman GH; Kuderer NM
    Crit Rev Oncol Hematol; 2004 May; 50(2):129-46. PubMed ID: 15157662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia.
    Donohue R
    Oncol Nurs Forum; 2006 Nov; 33(2):347-52. PubMed ID: 16518450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.